Celltrion to sell 2 biosimilars through export subsidiary

Home > Business > Industry

print dictionary print

Celltrion to sell 2 biosimilars through export subsidiary

The Korean biopharmaceutical firm Celltrion Inc. said Friday that it has signed a deal with an affiliate to sell two biosimilars - Truxmia and Herzuma.

Under the deal, worth 151.4 billion won ($136.4 million) and equivalent to nearly 16 percent of the company’s annual sales, Celltrion will sell the biosimilars to Celltrion Healthcare, which handles Celltrion’s overseas business.

Truxima will be used in the treatment of diseases including rheumatoid arthritis and non-Hodgkin’s lymphoma, a type of leukemia.

Herzuma is a drug to treat breast cancer.


More in Industry

Samsung's Galaxy S21 series expected to outsell S20

Posco receives first shipment delivered by LNG carrier

Renault Samsung offers voluntary retirement as woes continue

SK Innovation acquires stake in Chinese BaaS operator

LG may hang up on smartphone business

Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)

What’s Popular Now